Over 200,000 units of retatrutide: May & June 2026 freight fraud report

August 28, 2026

May and June 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.

August 24, 2026: Study finds black market retatrutide is not as effective as the clinical trial versions

August 26, 2026

Black market users lost an average of 4.7%, 5.3%, and 7.2% of their weight after taking “reta” for three months, six months, and one year, respectively. Those in clinical trials lost an average of 5.7%, 11.9%, and 15.5% over the same time intervals.

The retatrutide black market: Patient safety groups warn of growing risks from understudied drugs

August 18, 2026

The unapproved retatrutide market holds immense safety risks, and patient safety and consumer groups are urging regulators, law enforcement, and the healthcare community to act decisively to protect Americans.

August 17, 2026: Appeals court finds imported medications have “material, not theoretical” differences

August 18, 2026

The U.S. Court of Appeals for the Fourth Circuit upheld the preliminary injunction filed against alternative funding programs and related vendors, in a major win for Gilead Sciences’ civil case.

He just wanted to get back to work: a simple backache ended in tragedy

August 17, 2026

35-year-old Tyreek Lewis just wanted his back pain to stop, but pain relief would mean time off from work, hours of tests, and extra appointments. So he took what looked like a simple shortcut. It killed him, and altered his family’s life forever.

Statement from Partnership for Safe Medicines on new litigation alleging illegal distribution of retatrutide

August 13, 2026

Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.

Statement from Partnership for Safe Medicines on the appeals court’s decision in Gilead Sciences v. Meritain Health

August 13, 2026

The appeals court’s decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.

Like your information on video? Subscribe to our YouTube playlist!

youtube-video-thumbnail

What are research-grade drugs? They're not safe medicine.

youtube-video-thumbnail
youtube-video-thumbnail

Click the images below to see more recent videos.